Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency

European Journal of Endocrinology

Volumn 171, Issue 3, 2014, Pages 369-377

  Nilsson, A G ^a   Marelli, C ^b   Fitts, D ^c   Bergthorsdottir, R ^a   Burman, P ^d   Dahlqvist, P ^e   Ekman, B ^f   Eden Engstrom B ^g   Olsson, T ^e   Ragnarsson, O ^e   Ryberg, M ^f   Wahlberg, J ^h   Lennernas H ^i,j   Skrtic, S ^a   Johannsson, G ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ViroPharma Chatsworth House   (United Kingdom)

^c ViroPharm Incorporated   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g University Hospital   (United States)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE;

ACUTE PANCREATITIS; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADULT; ARTHRALGIA; ARTICLE; CHICKENPOX; CHOLELITHIASIS; COLITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FORMULATION; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PNEUMONIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VERTIGO; VIRUS INFECTION; BLOOD; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADRENAL INSUFFICIENCY; ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NASOPHARYNGITIS; PROSPECTIVE STUDIES;

EID: 84907206929     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0327     Document Type: Article

References (22)

1. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, VentzM, QuinklerM& Allolio B. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. European Journal of Endocrinology 2010 162 597-602. (doi:10.1530/EJE-09-0884)
2. Dunlop D. Eighty-six cases of Addison's disease. BMJ 1963 2 887-891. (doi:10.1136/bmj.2.5362.887)
3. Forss M, Batcheller G, Skrtic S & Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocrine Disorder 2012 12 8. (doi:10.1186/1472-6823-12-8)
4. ErichsenMM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, FougnerKJ, Berg TJ, BollerslevJ, MellaBet al.Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations froma Norwegian registry. Journal of Clinical Endocrinology and Metabolism 2009 94 4882-4890. (doi:10.1210/jc.2009-1368)
5. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT & Ross RJ. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology 2004 61 367-375. (doi:10.1111/j.1365-2265.2004.02106.x)
6. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC & Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology and Metabolism 1991 72 39-45. (doi:10.1210/jcem-72-1-39)
7. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W & Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 3912-3922. (doi:10.1210/jc.2007-0685)
8. Bouillon R. Acute adrenal insufficiency. Endocrinology and Metabolism Clinics of North America 2006 35 767-775 (ix). (doi:10.1016/j.ecl.2006. 09.004)
9. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A & Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961. (doi:10.1210/jc.2006-0524)
10. Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, Blomqvist P & Kampe O. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clinical Endocrinology 2008 69 697-704. (doi:10.1111/j.1365-2265.2008.03340.x)
11. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A & Johannsson G. Premature mortality in patients with Addison's disease: a populationbased study. Journal of Clinical Endocrinology and Metabolism 2006 91 4849-4853. (doi:10.1210/jc.2006-0076)
12. Erichsen MM, Lovas K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, Berg JP, Mella B & Husebye ES. Normal overallmortality rate in Addison's disease, but young patients are at risk of premature death. European Journal of Endocrinology 2009 160 233-237. (doi:10.1530/EJE-08-0550)
13. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W & Ross RJ. Modified-release hydrocortisone to provide circadian cortisol profiles. Journal of Clinical Endocrinology and Metabolism 2009 94 1548-1554. (doi:10.1210/jc.2008-2380)
14. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology 1997 46 263-268. (doi:10.1046/j.1365-2265.1997.1340955.x)
15. Oelkers W. Adrenal insufficiency. New England Journal of Medicine 1996 335 1206-1212. (doi:10.1056/NEJM199610173351607)
16. Wallace WH, Crowne EC, Shalet SM, Moore C, Gibson S, Littley MD & White A. Episodic ACTH and cortisol secretion in normal children. Clinical Endocrinology 1991 34 215-221. (doi:10.1111/j.1365-2265. 1991.tb00297.x)
17. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T & Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-releasehydrocortisone tablet: a pharmacokinetic study.European Journal of Endocrinology 2009 161 119-130. (doi:10.1530/EJE-09-0170)
18. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstrom BE, Olsson T, Ragnarsson O, Ryberg M et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomised trial of a novel hydrocortisone dual-release formulation. Journal of Clinical Endocrinology and Metabolism 2012 97 473-481. (doi:10.1210/jc.2011-1926)
19. Toothaker RD, Craig WA & Welling PG. Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. Journal of Pharmaceutical Sciences 1982 71 1182-1185. (doi:10.1002/jps.2600711029)
20. Benson S, Neumann P, Unger N, Schedlowski M, Mann K, Elsenbruch S & Petersenn S. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. European Journal of Endocrinology 2012 167 679-685. (doi:10.1530/EJE-12-0351)
21. Ekman B, Bachrach-LindstromM, Lindstrom T, Wahlberg J, Blomgren J & Arnqvist HJ. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clinical Endocrinology 2012 77 18-25. (doi:10.1111/j.1365-2265.2012.04352.x)
22. Smans LC, Souverein PC, Leufkens HG, Hoepelman AI & Zelissen PM. Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. European Journal of Endocrinology 2013 168 609-614. (doi:10.1530/EJE-12-0879)